News

U.S. Presses Pharma to Boost International Drug Prices to Lower Costs at Home

U.S. officials have proposed a "most favored nation" (MFN) pricing framework, in which prices paid in the United States would align with the lowest levels negotiated by other developed countries. In exchange, the administration has pledged to support drugmakers in their global negotiations, leveraging upcoming trade talks and tariff policy as bargaining chips.

• By Newsdesk
• Washington
• Aug 10, 2025

News

The Trump administration is spearheading private discussions with top pharmaceutical firms aimed at compelling them to raise drug prices in Europe and other affluent markets—part of a strategy intended to ease the financial burden of prescription medicines on American patients.

U.S. officials have proposed a "most favored nation" (MFN) pricing framework, in which prices paid in the United States would align with the lowest levels negotiated by other developed countries. In exchange, the administration has pledged to support drugmakers in their global negotiations, leveraging upcoming trade talks and tariff policy as bargaining chips.

Multiple confidential meetings over recent months have explored how foreign pricing adjustments could preserve research and development funding while reducing U.S. out-of-pocket expenses. One senior White House official described the effort as a "collaborative" endeavor with industry leaders.

Eli Lilly’s CEO, David Ricks, expressed support for the idea of long-term pricing parity between the U.S. and Europe—but acknowledged that making European countries agree to higher prices could be a major hurdle, given that they typically wield strong price-setting power.

Health economists emphasize that U.S. pharmaceutical profits currently outpace the needs of global innovation, suggesting that American prices could drop without shifting costs onto other nations. Still, pharmaceutical executives worry cost-sharing across markets could undermine their R&D pipelines.

A European drug industry executive—speaking on condition of anonymity—confirmed that increasing foreign drug prices has become the administration’s top priority in discussions with industry trade groups like PhRMA. These talks are reportedly being coordinated alongside broader trade negotiations with the EU and UK.

Yet in Europe, skepticism runs deep. Analyst Anna Kaltenboeck warns that governments there can refuse to purchase medications deemed too costly. “Prices can come down in the United States without being increased in other countries, and we can still get innovation,” she said, pointing to earlier studies showing U.S. drug revenues alone fully fund global R&D efforts.

With the U.S. currently paying as much as three times more for brand-name drugs than peer nations, this aggressive diplomatic and economic push signals how high-stakes and complex the drug-pricing debate has become.

(Source: Reuters)